Conjugated Monoclonal Antibodies Market Report 2026

The conjugated monoclonal antibodies market size has grown strongly in recent years. It will grow from $12.09 billion in 2025 to $12.86 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to limited availability of conjugated monoclonal antibodies, reliance on conventional chemotherapy, growing cancer prevalence, increasing research on targeted therapies, initial approvals of adc-based drugs.

The conjugated monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $16.76 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to development of new linker technologies, expansion of adc applications to multiple cancers, rising adoption of personalized medicine approaches, increasing funding for oncology research, growing number of clinical trials and pipeline drugs. Major trends in the forecast period include rising adoption of conjugated monoclonal antibodies in oncology, growth in targeted therapies for blood and solid tumors, development of cleavable and non-cleavable linker technologies, expansion of personalized medicine and precision oncology, increasing investment in clinical trials and cancer research.

The high prevalence of cancer is expected to drive the growth of the conjugated monoclonal antibodies market in the coming years. Cancer is a group of diseases marked by the uncontrolled growth and spread of abnormal cells within the body. The increasing incidence of cancer is largely associated with aging populations, as the likelihood of developing cancer rises with age and more people are living longer than in previous generations. Conjugated monoclonal antibodies support cancer treatment by precisely targeting malignant cells and delivering powerful therapeutic agents directly to them, thereby enhancing treatment effectiveness while reducing harm to healthy tissues. For example, in October 2025, according to NHS England, a UK-based publicly funded healthcare system, there were 354,820 new cancer diagnoses recorded in 2023, representing an increase of 8,605 cases compared with 2022. Consequently, the high prevalence of cancer is contributing to the expansion of the conjugated monoclonal antibodies market.

Major companies operating in the conjugated monoclonal antibodies market are increasingly adopting strategic partnership approaches to deliver comprehensive solutions and strengthen their technological and commercial capabilities. Strategic partnerships involve organizations combining their respective strengths and resources to achieve shared objectives and long-term success. For instance, in July 2023, BeiGene Ltd., a US-based biotechnology company, entered into a partnership with Duality Biologics, a China-based clinical-stage biotechnology company. Through this collaboration, the partners aim to develop and commercialize a preclinical antibody-drug conjugate therapy for patients with selected solid tumors, leveraging their combined expertise to accelerate development and commercialization.

In June 2023, Lonza Group AG, a Switzerland-based manufacturing company, acquired Synaffix BV for an undisclosed amount. With this acquisition, Lonza sought to enhance its development and manufacturing capabilities, broaden its antibody-drug conjugate portfolio, and gain access to Synaffix’s pipeline of ADC candidates and related technologies. Synaffix BV is a Netherlands-based company focused on antibody-drug conjugate technologies and solutions.

Major companies operating in the conjugated monoclonal antibodies market are Pfizer Inc., F. Hoffmann-La Roche AG, Bristol -Myers Squibb, Merck & Co. Inc., Immunomedics Inc., Takeda Pharmaceuticals Industries Ltd., Daiichi Sankyo Company Limited, Actinium Pharmaceutical, Nordic Nanovector Inc., AbbVie Inc., Bayer AG, AstraZeneca plc, Novartis AG, Amgen, Celgene, Genzyme, Incyte Corporation, MorphoSys AG, Regeneron Pharmaceuticals, Seattle Genetics.

North America was the largest region in the conjugated monoclonal antibody market in 2025. The Middle East is expected to be the fastest-growing region in the global conjugated monoclonal antibodies market share during the forecast period. The regions covered in the conjugated monoclonal antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the conjugated monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the conjugated monoclonal antibodies market by increasing costs of imported active pharmaceutical ingredients, monoclonal antibodies, and linker reagents. Segments like cleavable and non-cleavable linker drugs are most affected, particularly in North America and Europe, which rely heavily on imports. This has led to higher treatment costs and supply chain delays. On the positive side, tariffs have encouraged local production, innovation in linker chemistry, and development of cost-optimized ADC therapies.

The conjugated monoclonal antibodies market research report is one of a series of new reports that provides conjugated monoclonal antibodies market statistics, including conjugated monoclonal antibodies industry global market size, regional shares, competitors with a conjugated monoclonal antibodies market share, detailed conjugated monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the conjugated monoclonal antibodies industry. This conjugated monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Conjugated monoclonal antibodies are compounds created by chemically linking a monoclonal antibody to a drug. The monoclonal antibody attaches to specific proteins or receptors found on particular cell types, such as cancer cells. Once bound, the linked drug is delivered into these cells, where it destroys them while largely sparing healthy cells.

The primary drugs in the conjugated monoclonal antibodies category include Adcetris and Kadcyla. Adcetris is a branded pharmaceutical used to treat adults with certain types of lymphoma, a cancer that affects the lymphatic system and lymphocytes, which are white blood cells. The key technologies involved include cleavable linkers and non-cleavable linkers, and these therapies are used in the treatment of blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumors, and others.

The conjugated monoclonal antibodies market consists of sales of Brentuximab vedotin and Ado-trastuzumab emtansine. Values in this market are 'factory gate values,' that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.